Skip to main content
Clinical Trials/NCT03166423
NCT03166423
Unknown
Phase 1

Clinical Trial Phase I-II of Efficacy and Safety of Snail Slime and Natural Extracts for Healing in Diabetic Foot Ulcers

University of Chile4 sites in 1 country90 target enrollmentNovember 12, 2015

Overview

Phase
Phase 1
Intervention
MU001 patches (Investigational)
Conditions
Diabetic Foot Ulcer
Sponsor
University of Chile
Enrollment
90
Locations
4
Primary Endpoint
Incidence rate of healing until 60 days or less
Last Updated
8 years ago

Overview

Brief Summary

The primary objective is to evaluate the efficacy and safety of the use of a formulation of snail slime and natural extracts, for the curative treatment of ulcer wonds in diabetic foot.

The secondary objetives:

  1. To evaluate the efficacy of the use of a formulation of snail slime Helix aspersa Müller and natural extracts (MU001) for the curative treatment of ulcer wonds in diabetic foot with respect to the standard of care, by means the application of patchs that containing the formulation in a treatment period of until 60 days.
  2. To determine the safety of the use of a formulation of snail slime Helix aspersa Müller and natural extracts (MU001) in diabetic individuals in a treatment period of until 60 days.

Detailed Description

Clinical Study of phase I-II, controlled, simple blind (in relation with biostatistical analysis), randomized, of formulation that containing snail slime Helix aspersa Müller (Cryptophalus aspersus), natural calendula extract, propolis and excipients (MU001). The formulation in study MU001 wil be added to the standard of care for healing in diabetic foot indicated. The period of recruitment estimated will be 4 month and the follow-up of the patients will be of until 60 days.

Registry
clinicaltrials.gov
Start Date
November 12, 2015
End Date
July 1, 2017
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
University of Chile
Responsible Party
Principal Investigator
Principal Investigator

Luis Quiñones Sepulveda

Dr.

University of Chile

Eligibility Criteria

Inclusion Criteria

  • Diabetes type 2
  • Unilateral ulcers
  • Grade 1 or grade 2 Wagner ulcers.
  • Without infection (except onychomycosis)
  • Network family, hygiene, adherence and compliance appropiated

Exclusion Criteria

  • Bilateral ulcers
  • Medical conditions with high risk (cancer, allergies)
  • Consum of abuse drugs

Arms & Interventions

MU001 patches (Investigational)

Patches MU001 (snail slime, calendula extract and propolis extract) more standard of care. Two or three application for week. Treatment until 60 days. Patches MU001 (snail slime, calendula extract and propolis extract) on health zone. Three days of treatment.

Intervention: MU001 patches (Investigational)

Conventional patches (Control)

Conventional patches approved for diabetic foot ulcers more standard of care. Two or three application for week. Treatment until 60 days.

Intervention: Conventional patches (Control)

Outcomes

Primary Outcomes

Incidence rate of healing until 60 days or less

Time Frame: 60 days

Incidence of healing measured with Wagner ulcer classification

Secondary Outcomes

  • Time to healing until 60 days or less(60 days)
  • Incidence of treatment-emergent adverse events (Safety and Tolerability) of a formulation of snail slime and natural extracts in ulcer wounds in diabetics foot(60 days)
  • Incidence of treatment-emergent adverse events (Safety and Tolerability) of a formulation of snail slime and natural extracts in healthy skin(3 days)

Study Sites (4)

Loading locations...

Similar Trials